≥99% purity · Canadian lab tested · Lyophilized · RT3-RETA
Triple receptor agonist for metabolic research. ≥99% purity · Lyophilized · 10, 30 or 60 mg. For research use only.
Retatrutide (RT3) is a triple receptor agonist with activity at GLP-1, GIP and glucagon receptors, supplied as a lyophilized reference compound for in-vitro receptor pharmacology.
REPORTED MECHANISM (IN VITRO / PRECLINICAL)
RT3 shows concentration-dependent agonism at all three receptor subtypes in cell-based assays. Changes in food intake, energy expenditure and glucose handling have been reported in rodent models only; no human data is presented or implied.
IN-VITRO / PRECLINICAL RESEARCH APPLICATIONS
– Triple receptor binding and selectivity assays
– cAMP accumulation and signalling studies
– Glucose-uptake assays in cultured cell lines
– Adipocyte lipid-storage and mitochondrial assays
– Comparative agonist potency profiling
PRODUCT SPECIFICATIONS
– Quantity: 10, 30 or 60 mg per vial
– Purity: ≥99% (HPLC & Mass Spectrometry verified)
– Form: Lyophilized powder
– Reconstitution: Bacteriostatic water recommended
– Storage: Below −20°C long-term · 4°C up to 6 weeks
– Testing: Independent Canadian 3rd-party laboratory
– COA: Available on request
For laboratory research use only. Not for human or veterinary use, consumption, or diagnostic procedures. Not evaluated by Health Canada or the FDA.
Incretin Analogues — All research should be conducted in a controlled laboratory environment by qualified personnel.
Store below −20°C for long-term stability. Refrigeration at 4°C acceptable for up to 2 years. Room temperature tolerance of 4–6 weeks if protected from direct sunlight.
